canadian stocks


At $257,200.00 a share, investing in Berkshire Hathaway Inc. (NYSE: BRK.A) is simply not an option for most retail investors like us. But the nearly 50 other “Warren Buffett stocks” that Berkshire invests in come at a much lower price point.

While we at Money Morning don’t recommend all of Warren Buffett’s stock picks for retail investors, our experts do like a lot of them. One in particular is a stock Money Morning Director of Technology & Venture Capital Michael A. Robinson recently recommended.


But before we get to the stock pick, here’s a list of the 10 top-performing Warren Buffett stocks so far this year…

Company YTD Gains
Moody’s Corp. (NYSE: MCO) 34.25%
Apple Inc. (Nasdaq: AAPL) 30.24%
Verisign Inc. (Nasdaq: VRSN) 29.88%
Restaurant Brands Inc. (NYSE: QSR) 29.16%
WABCO Holdings Inc. (NYSE: WBC) 28.97%
Visa Inc. (NYSE: V) 26.20%
Liberty Sirius XM Group Class C (Nasdaq: LSXMK) 24.54%
MasterCard Inc. (NYSE: MA) 24.35%
Liberty Sirius XM Group Class A (Nasdaq: LSXMA) 22.89%
Sirius XM Holdings Inc. (Nasdaq: SIRI) 22.81%


Again, we don’t recommend all of the stocks above for retail investors. After all, Warren Buffett is one of the most wealthy and legendary investors in history. He has a completely different set of goals from us.

canadian stocks: Omega Healthcare Investors, Inc.(OHI)

Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    Or, consider Omega Healthcare Investors (OHI). The Maryland-based company invests heavily in hospital properties and health care facilities, with a special emphasis on nursing facilities.

  • [By Paul Ausick]

    Omega Healthcare Investors Inc. (NYSE: OHI) dropped about 2.6% Monday to post a new 52-week low of $26.43 after closing at $27.14 on Friday. The 52-week high is $35.14. Volume was around 5.3 million, more than double the daily average of around 2.3 million. The healthcare REIT had now specific news.

canadian stocks: Interpublic Group of Companies, Inc. (The)(IPG)

Advisors’ Opinion:

  • [By Craig Jones]

    On CNBC's "Fast Money Halftime Report", Jon Najarian spoke about unusually high options activity in Arconic Inc (NYSE: ARNC) and Interpublic Group of Companies Inc (NYSE: IPG).

  • [By Laurie Kulikowski]

    Interpublic is our income play in our media universe. While other stocks we cover offer a higher yield than IPG’s 2.1%, the company’s double digit EPS growth projections for 2016 (following an estimated 18% in 2015) will also likely be a driver of outperformance for the year. While results can be somewhat volatile for IPG, we would point to record new business win backlog this year, which improves our conviction that the better than average recent organic revenue growth trends will continue next year. At 18x our 2016 EPS estimate, we find IPG shares attractive at current levels for another projected year of healthy double digit total returns. 

  • [By Paul Ausick]

    The Interpublic Group of Companies Inc. (NYSE: IPG) dropped about 2.3% Thursday to post a new 52-week low of $20.94 after closing Wednesday at $21.44. The 52-week high is $25.71. Volume reached nearly 13 million shares traded, nearly 3 times the daily average of around 3.8 million. The company had no specific news, but Tuesday’s weak earnings report continues to weigh on the share price.

  • [By Laurie Kulikowski]

    Net operating cash flow has significantly increased by 59.42% to $280.90 million when compared to the same quarter last year. In addition, INTERPUBLIC GROUP OF COS has also vastly surpassed the industry average cash flow growth rate of 8.14%.


     

canadian stocks: bluebird bio, Inc.(BLUE)

Advisors’ Opinion:

  • [By Todd Campbell]

    After updating investors on its wide-ranging gene therapy research program at a key industry conference early in the month,shares ofbluebird bio(NASDAQ:BLUE) surged 20.7% higher in January,according toS&P Global Market Intelligence.

canadian stocks: Huntsman Corporation(HUN)


Advisors’ Opinion:

  • [By Lee Jackson]

    Huntsman Corp. (NYSE: HUN) had its executive chairman selling stock last week. Jon Huntsman parted with 600,000 shares, and the share priceranged from $17.25 to $17.27. The total for the trade was posted at $10 million.The company manufactures and sells differentiated organic and inorganic chemical products worldwide. The stock traded Friday at $18.10, so some left on that table as well.

  • [By Paul Ausick]

    Venator Materials PLC is a maker of titanium dioxide pigments and additives. The company is being spun out of Huntsman Corp. (NYSE: HUN) and plans to offer 22.7 million shares in an expected price range of $20 to $21, raising $465 million at an implied market cap of $2.18 billion. Underwriters include Citi, Goldman Sachs, BofA/Merrill Lynch, J.P. Morgan, Barclays, Deutsche Bank, UBS Investment Bank, RBC Capital Markets, Moelis & Company, HSBC Corp., Nomura Securities, SunTrust Robinson Humphrey, Academy Securities, and Commerzbank Capital. Shares are scheduled to price Wednesday and begin trading Thursday on the New York Stock Exchange under the ticker symbol VNTR.

canadian stocks: OncoMed Pharmaceuticals, Inc.(OMED)


Advisors’ Opinion:

  • [By Teresa Rivas]

    OncoMed Pharmaceuticals (OMED) has lost more than a third of its value Monday, after Bayer decided not to exercise its option to license the firms Phase II-ready WNT pathway inhibitors Vantictumab and Ipafricept, which treat pancreatic cancer.

    Pixabay

    That wasnt the only bad news, however, as the firms randomized-controlled Phase II “YOSEMITE” trial of pancreatic cancer drug demcizumab also missed its primary endpoint.


    Leerinks Michael Schmidt and his team reiterated a Market Perform rating on the stock Monday, and lowered their price target from $10 to $6 on the news, calling it a “double setback” for OncoMed.

    More detail from the note:

    This is a major setback for OMED and in our view for the cancer stem cell targets more broadly, which have been a difficult area of drug development. We’ve been cautious on the probability-of-success of these agents and see more promise on OMED’s recent efforts in building a second area of focus in immuno-oncology. Going forward, OMED plans to review and prioritize its R&D pipeline after results from the still pending tarextumab Phase II “PINNACLE” trial in small cell lung cancer (SCLC) and data from the demcizumab “DENALI” trial in NSCLC are available in 2Q17. We remain MP rated in light of the uncertainties around OMED’s pipeline and strategy at this point. We previously assigned a 30% probability of success (POS) to demcizumab which we now have removed from our model. We also think chances that CELG will opt-into this program are slim and we have removed associated POS-adjusted milestone payments from our model. OMED has cash to run operations through 3Q18.


    OncoMed is down 36.1% to $5.60 this afternoon.

  • [By Paul Ausick]

    OncoMed Pharmaceuticals Inc. (NASDAQ: OMED) dropped about 5.3% Wednesday to post a new 52-week low of $4.69 after closing at $4.95 on Tuesday. The stock’s 52-week high is $15.49. Volume was more than double the daily average of around 270,000 shares. The company had no specific news Wednesday.

  • [By Paul Ausick]

    OncoMed Pharmaceuticals Inc. (NASDAQ: OMED) dropped nearly 44% Monday to post a new 52-week low of $4.94 after closing Friday at $8.76. The stock’s 52-week high is $15.49. Volume of about 3.3 million shares was nearly 20 times the daily average of around 182,000. A proposed deal with Bayer AG fell through and one of the company’s drugs failed a phase 2 clinical trial.

canadian stocks: Take-Two Interactive Software, Inc.(TTWO)


Advisors’ Opinion:

  • [By Emily Stewart]

    Paulson purchased one million shares of Take-Two Interactive Software (TTWO) last quarter. As of the end of the period, the stake is worth $37.9 million.

    Take-Two Interactive is a developer, marketer and publisher of interactive entertainment for consumers around the globe. The company develops and publishes products through its two wholly owned labels: Rockstar Games and 2K. It has a $3.6 billion market cap and trades at a P/E of 165.16. 

  • [By John Ballard]

    Investors interested in the video game industry should find both Electronic Arts (NASDAQ:EA) and Take-Two Interactive Software(NASDAQ:TTWO) appealing. Both are expanding margins as digital revenue opportunities from in-game content and mobile gaming continue to propel the industry forward.

  • [By John Ballard]

    Take-Two Interactive (NASDAQ:TTWO) has been on a roll in the last several years following extremely strong sales of Grand Theft Auto V. Even after a 300% gain over the last five years, the stock still trades for a reasonableforward price-to-earnings ratio of 24 times fiscal 2018 earnings estimates.Let’s review the important drivers for the video game company in the year ahead and beyond.

Leave a Reply

Your email address will not be published. Required fields are marked *